A. Mann

发表

J. Oxford, Rob Lambkin-Williams, A. Mann, 1968, Leaving The Arena.

A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity.

Rob Lambkin-Williams, A. Mann, Y. Barenholz, 2011, Vaccine.

Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.

Rob Lambkin-Williams, A. Mann, Y. Barenholz, 2010, Vaccine.

Viral load drives disease in humans experimentally infected with respiratory syncytial virus.

J. Oxford, Rob Lambkin-Williams, A. Mann, 2010, American journal of respiratory and critical care medicine.

A designer drug against influenza: the NA inhibitor oseltamivir (Tamiflu).

J. Oxford, A. Mann, R. Lambkin, 2003, Expert review of anti-infective therapy.

Preclinical Evaluation of a Replication-Deficient Intranasal ΔNS1 H5N1 Influenza Vaccine

J. Oxford, A. Mann, B. Ferko, 2009, PloS one.

Predictive value of response to treatment of T-lymphocyte subpopulations in idiopathic pulmonary fibrosis.

A. Mann, Y. Schwarz, J. Greif, 1998, The European respiratory journal.

A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

Intranasal H5N1 Vaccines, Adjuvanted with Chitosan Derivatives, Protect Ferrets against Highly Pathogenic Influenza Intranasal and Intratracheal Challenge

J. Oxford, Rob Lambkin-Williams, A. Mann, 2014, PloS one.

Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine.

J. Oxford, A. Mann, J. Viret, 2004, Vaccine.

An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection

J. Oxford, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.

A. Mann, P. Dormitzer, A. Gurtman, 2022, The New England journal of medicine.

Minimal transmission in an influenza A (H3N2) human challenge-transmission model within a controlled exposure environment

Rob Lambkin-Williams, A. Mann, S. Cauchemez, 2019, PLoS pathogens.

Minimal transmission in an influenza A (H3N2) human challenge- 5 transmission model within a controlled exposure environment in a controlled environment

A. Mann, J. Nguyen-Van-Tam, D. Milton, 2020 .

Human infection studies: Key considerations for challenge agent development and production

A. Mann, Emma Smith, S. Balasingam, 2022, Wellcome open research.

Minimal Transmission in an Influenza A (H3N2) Human Challenge-Transmission Model with Exposure Events in a Controlled Environment

Paul Jacob, Bueno de Mesquita, Rob Lambkin-Williams, 2019, SSRN Electronic Journal.

Influenza A (H3) illness and viral aerosol shedding from symptomatic naturally infected and experimentally infected cases

Rob Lambkin-Williams, A. Mann, A. Gilbert, 2020, Influenza and other respiratory viruses.

Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors.

J. Oxford, A. Mann, S. Balasingam, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

The Effect of Influenza Virus on the Human Oropharyngeal Microbiome

Rob Lambkin-Williams, A. Mann, A. Gilbert, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection.

J. Oxford, A. Mann, S. Balasingam, 2006, Vaccine.

Animal models in influenza vaccine testing

J. Oxford, Rob Lambkin-Williams, A. Mann, 2008, Expert review of vaccines.

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults

A. Mann, N. Ferguson, C. Hopkins, 2022, Nature Medicine.

Correction: Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

Re-Inventing the Common Cold Institute for the 21st Century

Rob Lambkin-Williams, A. Mann, A. Gilbert, 2016 .

A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans

J. Oxford, Rob Lambkin-Williams, A. Mann, 2015, Clinical and Vaccine Immunology.

Running Title: Live virus challenge trial of T cell influenza vaccine 4

J. Oxford, Rob Lambkin-Williams, A. Mann, 2015 .

A plant‐produced influenza subunit vaccine protects ferrets against virus challenge

J. Oxford, A. Mann, K. Musiychuk, 2008, Influenza and other respiratory viruses.

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge

A. Mann, N. Ferguson, C. Hopkins, 2022 .

The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics

Rob Lambkin-Williams, A. Mann, A. Gilbert, 2018, Respiratory Research.

Considerations for Pregnant Dental and Health Care Workers amid COVID-19

A. Mann, A. Letra, A. Dahiya, 2020, JDR clinical and translational research.

Inhibition of viral and bacterial trigger-stimulated prostaglandin E2 by a throat lozenge containing flurbiprofen: An in vitro study using a human respiratory epithelial cell line

Rob Lambkin-Williams, A. Mann, A. Shephard, 2020, SAGE open medicine.

Influenza — The Chameleon Virus

Alex Mann, J. Oxford, A. Mann, 2003 .

The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2018, BMC Research Notes.

Correlation between Human Leukocyte Antigen Class II Alleles and HAI Titers Detected Post-Influenza Vaccination

J. Oxford, Rob Lambkin-Williams, A. Mann, 2013, PloS one.

Differential evolution of peripheral cytokine levels in symptomatic and asymptomatic responses to experimental influenza virus challenge

Ricardo Henao, Rob Lambkin-Williams, A. Mann, 2016, Clinical and experimental immunology.

Comparing Influenza and Rsv Viral and Disease Dynamics in Experimentally Infected Adults Predicts Clinical Effectiveness of Rsv Antivirals

J. Oxford, Rob Lambkin-Williams, A. Mann, 2013, Antiviral therapy.

Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study

A. Mann, Jie Zhou, N. Ferguson, 2023, The Lancet Microbe.

SARS-CoV-2 human challenge reveals single-gene blood transcriptional biomarkers that discriminate early and late phases of acute respiratory viral infections.

A. Mann, B. Chain, M. Kaforou, 2023, medRxiv.

Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic

Mohammed I. Alghamdi, Kevin C. Chu, E. R. Lloyd, 2021, The British journal of surgery.

Human SARS-CoV-2 challenge resolves local and systemic response dynamics

A. Mann, E. Prigmore, R. Chambers, 2023, medRxiv.

The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process

Andrew P. Catchpole, Daniel J. Fullen, Nicolas Noulin, 2018, BMC Research Notes.

Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.

Rob Lambkin-Williams, A. Mann, Y. Barenholz, 2010, Vaccine.

A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity.

Rob Lambkin-Williams, A. Mann, Y. Barenholz, 2011, Vaccine.

The Threat of Avian Influenza H5N1: ‘Do We Have the Tools for the Job?’

J. Oxford, Rob Lambkin-Williams, A. Mann, 2007, Antiviral chemistry & chemotherapy.

Behavioral Interference Between Sympatric Reindeer and Domesticated Sheep in Norway

A. Mann, S. Moe, E. Reimers, 2012 .

RV568, a narrow spectrum kinase inhibitor (NSKI), inhibits virus induced nasal interleukin-8 (IL8) in the human viral challenge model where healthy adult male volunteers were experimentally inoculated with live respiratory syncytial virus

Rob Lambkin-Williams, A. Mann, A. Gilbert, 2013 .